$ESPR
Esperion Therapeutics, Inc. Stock $espr

$espr Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000162828022011885 Filed on May 03, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$18.84M	$7.978M
YoY Change	136.1%	333.59%
Cost Of Revenue	$7.125M	$1.800M
YoY Change	295.83%
Gross Profit	$11.71M	$6.200M
YoY Change	88.89%	244.44%
Gross Profit Margin	62.17%	77.71%
Selling, General & Admin	$30.38M	$61.06M
YoY Change	-50.25%	46.95%
% of Gross Profit	259.42%	984.9%
Research & Development	$24.32M	$27.95M
YoY Change	-13.0%	-19.45%
% of Gross Profit	207.66%	450.87%
Depreciation & Amortization	$153.0K	$153.0K
YoY Change	0.0%	44.34%
% of Gross Profit	1.31%	2.47%
Operating Expenses	$61.83M	$90.80M
YoY Change	-31.91%	19.03%
Operating Profit	-$42.99M	-$82.82M
YoY Change	-48.1%	11.25%
Interest Expense	$14.06M	$8.125M
YoY Change	73.07%	94.8%
% of Operating Profit
Other Income/Expense, Net	$320.0K	$14.00K
YoY Change	2185.71%	-96.2%
Pretax Income	-$56.73M	-$90.90M
YoY Change	-37.59%	16.24%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$56.73M	-$90.94M
YoY Change	-37.61%	16.21%
Net Earnings / Revenue	-301.18%	-1139.82%
Basic Earnings Per Share	-$0.93	-$3.50
Diluted Earnings Per Share	-$0.93	-$3.50
COMMON SHARES
Basic Shares Outstanding	60.95M shares	25.99M shares
Diluted Shares Outstanding	60.95M shares	25.99M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$218.5M	$217.9M
YoY Change	0.28%	38.51%
Cash & Equivalents	$150.4M	$217.9M
Short-Term Investments	$68.14M
Other Short-Term Assets	$11.55M	$12.40M
YoY Change	-6.88%	-7.46%
Inventory	$35.65M	$20.03M
Prepaid Expenses
Receivables	$25.12M	$17.26M
Other Receivables	$0.00	$5.000M
Total Short-Term Assets	$290.8M	$272.6M
YoY Change	6.69%	57.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$511.0K	$1.123M
YoY Change	-54.5%	-22.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$50.00M
YoY Change
Total Long-Term Assets	$52.03M	$6.031M
YoY Change	762.78%	-14.0%
TOTAL ASSETS
Total Short-Term Assets	$290.8M	$272.6M
Total Long-Term Assets	$52.03M	$6.031M
Total Assets	$342.9M	$278.6M
YoY Change	23.06%	55.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.83M	$30.34M
YoY Change	-11.58%	100.75%
Accrued Expenses	$35.07M	$58.70M
YoY Change	-40.26%	21.78%
Deferred Revenue	$3.795M	$2.543M
YoY Change	49.23%	117.35%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$79.09M	$97.89M
YoY Change	-19.21%	33.27%
LONG-TERM LIABILITIES
Long-Term Debt	$258.7M	$271.7M
YoY Change	-4.79%
Other Long-Term Liabilities	$254.1M	$1.290M
YoY Change	19600.0%	-99.18%
Total Long-Term Liabilities	$512.8M	$1.290M
YoY Change	39652.56%	-99.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$79.09M	$97.89M
Total Long-Term Liabilities	$512.8M	$1.290M
Total Liabilities	$591.9M	$548.0M
YoY Change	8.01%	138.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.163B	-$928.2M
YoY Change	25.31%	20.0%
Common Stock	$61.00K	$26.00K
YoY Change	134.62%	-7.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$55.00M	$55.00M
YoY Change	0.0%
Treasury Stock Shares	1.994M shares	1.994M shares
Shareholders Equity	-$249.0M	-$269.4M
YoY Change
Total Liabilities & Shareholders Equity	$342.9M	$278.6M
YoY Change	23.06%	55.09%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$56.73M	-$90.94M
YoY Change	-37.61%	16.21%
Depreciation, Depletion And Amortization	$153.0K	$153.0K
YoY Change	0.0%	44.34%
Cash From Operating Activities	-$38.99M	-$89.07M
YoY Change	-56.22%	28.44%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$18.10M	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$18.10M	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$1.436M	$2.045M
YoY Change	-170.22%	-92.14%
NET CHANGE
Cash From Operating Activities	-$38.99M	-$89.07M
Cash From Investing Activities	-$18.10M	$0.00
Cash From Financing Activities	-$1.436M	$2.045M
Net Change In Cash	-$58.53M	-$87.02M
YoY Change	-32.74%	419.73%
FREE CASH FLOW
Cash From Operating Activities	-$38.99M	-$89.07M
Capital Expenditures		$0.00
Free Cash Flow		-$89.07M
YoY Change		28.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001434868
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-35986
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	Esperion Therapeutics, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1870780
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3891 Ranchero Drive, Suite 150
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	887-3903
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48108
CY2022Q1	dei	City Area Code CityAreaCode	734
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	ESPR
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63006619	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150364000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208892000	USD
CY2022Q1	us-gaap	Short Term Investments ShortTermInvestments	68138000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	50441000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25116000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22934000	USD
CY2022Q1	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	698000	USD
CY2021Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	1138000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	35654000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	34394000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10849000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11173000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	290819000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	328972000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50000000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50000000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	511000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	664000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1467000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1898000	USD
CY2022Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	USD
CY2022Q1	us-gaap	Assets Assets	342853000	USD
CY2021Q4	us-gaap	Assets Assets	381590000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	26829000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17559000	USD
CY2022Q1	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	3652000	USD
CY2021Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	7013000	USD
CY2022Q1	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	30200000	USD
CY2021Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	30410000	USD
CY2022Q1	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	13392000	USD
CY2021Q4	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	11295000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3795000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5683000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1217000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1392000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	79085000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	73352000	USD
CY2022Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	258678000	USD
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	258280000	USD
CY2022Q1	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	253445000	USD
CY2021Q4	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	245744000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	263000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	524000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	422000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	634000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	591893000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	578534000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63052765	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62873694	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	61000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	61000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	969268000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	964401000	USD
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	1994198	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1994198	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	54998000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	54998000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-263000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1163108000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1106377000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-249040000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-196944000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	342853000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	381590000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18836000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7978000	USD
CY2022Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	7125000	USD
CY2021Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1784000	USD
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	24319000	USD
CY2021Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	27954000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30381000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61064000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	61825000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	90802000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-42989000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-82824000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	14062000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	8125000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	320000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	14000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-56731000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-90935000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.93
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.93
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.50
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.50
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60954755	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60954755	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25991817	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25991817	shares
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-232000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56963000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-90935000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-96134000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2668000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1183000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5751000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-90935000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-269394000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-196944000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	431000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4436000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-232000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-56731000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-249040000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-56731000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-90935000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	153000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	153000	USD
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-173000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	398000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	400000	USD
CY2022Q1	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	11015000	USD
CY2021Q1	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	4925000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4436000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5751000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2182000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4942000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-764000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4866000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2100000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	881000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1260000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3894000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9393000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-21583000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3049000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	25042000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38990000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89068000	USD
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	18102000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18102000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2668000	USD
CY2022Q1	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	1217000	USD
CY2021Q1	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	573000	USD
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	219000	USD
CY2021Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	50000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1436000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2045000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-58528000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-87023000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	258892000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304962000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200364000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	217939000	USD
CY2022Q1	espr	Debt Issuance Costs Incurred But Not Yet Paid DebtIssuanceCostsIncurredButNotYetPaid	0	USD
CY2021Q1	espr	Debt Issuance Costs Incurred But Not Yet Paid DebtIssuanceCostsIncurredButNotYetPaid	445000	USD
CY2022Q1	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	6000	USD
CY2021Q1	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	4000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	50000000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	33846000	USD
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of March 31, 2022, ten customers accounted for all of the Company's net trade receivables and as of December 31, 2021, nine customers accounted for all the Company's net trade receivables.</span></div>
CY2022Q1	espr	Number Of Sources Of Revenue NumberOfSourcesOfRevenue	2	revenue_source
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	31850000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	440000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	663000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1368000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1881000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	35654000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	34394000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	209553000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	263000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	209290000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	239606000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	31000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	239575000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2022Q1	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	200000	USD
CY2022Q1	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	USD
CY2022Q1	espr	Fair Value Measurement Liability Transfers Between Levels FairValueMeasurementLiabilityTransfersBetweenLevels	0	USD
CY2021Q1	espr	Fair Value Measurement Liability Transfers Between Levels FairValueMeasurementLiabilityTransfersBetweenLevels	0	USD
CY2021Q1	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	USD
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	USD
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	USD
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	USD
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	USD
CY2020Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1994198	shares
CY2022Q1	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	71174	shares
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6330000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8809000	USD
CY2022Q1	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	16574000	USD
CY2021Q4	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	16192000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3278000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3917000	USD
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent	3975000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1325000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	43000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	167000	USD
CY2022Q1	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	30200000	USD
CY2021Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	30410000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3214537	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	38.38
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M4D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1042450	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.64
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	155728	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	47.81
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4101259	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.44
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M13D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	99000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4101259	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	29.44
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M13D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	99000	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2491684	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	39.84
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y1M2D
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	36964286	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.00
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	61900000	USD
CY2022Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	36964286	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	36964286	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.00
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.00
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	51816979	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13148231	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150364000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	217939000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208892000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304962000	USD
CY2022Q1	us-gaap	Restricted Cash RestrictedCash	50000000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	50000000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	200364000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	217939000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	258892000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304962000	USD

Files In Submission

Name	View Source	Status
0001628280-22-011885-index-headers.html	Edgar Link	pending
0001628280-22-011885-index.html	Edgar Link	pending
0001628280-22-011885.txt	Edgar Link	pending
0001628280-22-011885-xbrl.zip	Edgar Link	pending
espr-20220331.htm	Edgar Link	pending
espr-20220331.xsd	Edgar Link	pending
espr-20220331_cal.xml	Edgar Link	unprocessable
espr-20220331_def.xml	Edgar Link	unprocessable
espr-20220331_htm.xml	Edgar Link	completed
espr-20220331_lab.xml	Edgar Link	unprocessable
espr-20220331_pre.xml	Edgar Link	unprocessable
espr-ex311x03312022.htm	Edgar Link	pending
espr-ex312x03312022.htm	Edgar Link	pending
espr-ex321x03312022.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESPR
Esperion Therapeutics, Inc. Stock $espr

2022 Q1 Form 10-Q Financial Statement

#000162828022011885 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR Esperion Therapeutics, Inc. Stock $espr

2022 Q1 Form 10-Q Financial Statement

#000162828022011885 Filed on May 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR
Esperion Therapeutics, Inc. Stock $espr